AviadoBio Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://aviadobio.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)phase_1_2
1 (50.0%)A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Phase 1
Recruiting
- Conditions
- FTDFrontotemporal DementiaFTD-GRNDementia, Frontotemporal
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- AviadoBio Ltd
- Target Recruit Count
- 9
- Registration Number
- NCT06064890
- Locations
- 🇺🇸
The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Vanderbilt University Medical Centre, Nashville, Tennessee, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
News
Astellas and AviadoBio Partner in $2.2 Billion Deal to Advance Gene Therapy for Frontotemporal Dementia
Astellas Pharma and AviadoBio have entered into an agreement potentially worth $2.2 billion to advance AVB-101, a gene therapy for frontotemporal dementia with progranulin mutations (FTD-GRN).